Document is current
Any future updates will be listed below
-
Authors
Correll, Christoph U. https://orcid.org/0000-0002-7254-5646
Rubio, Jose M. https://orcid.org/0000-0002-0056-4135
Kane, John M. https://orcid.org/0000-0002-2628-9442
- License Information
-
More Information
Article History
Received: 25 September 2025
Accepted: 1 October 2025
First Online: 17 December 2025
Competing interests
: CUC has received honoraria from: AbbVie, Alkermes, Allergan, Angelini, Aristo, Autobahn, Boehringer-Ingelheim, Bristol-Meyers Squibb, Cardio Diagnostics, Cerevel, CNX Therapeutics, Compass Pathways, Darnitsa, Delpor, Denovo, Draig, Eli Lilly, Eumentis Therapeutics, Gedeon Richter, GH Research, Hikma, Holmusk, IntraCellular Therapies, Jamjoom Pharma, Janssen/J&J, Karuna, LB Pharma, Lundbeck, MedInCell, MedLink Global, Merck, Mindpax, Mitsubishi Tanabe Pharmaceuticals, Maplight, Mylan, Neumora Therapeutics, Neuraxpharm, Neurocrine, Neurelis, Neurosterix, NeuShen, Neusignal Therapeutics, Newron, Noven, Novo Nordisk, Orion Pharma, Otsuka, PPD Biotech, Recognify Life Science, Recordati, Relmada, Response Pharmaeutical, Reviva, Rovi, Saladax, Sanofi, Seqirus, Servier, Sumitomo Pharma America, Sunovion, Sun Pharma, Supernus, Tabuk, Takeda, Teva, Terran, Tolmar, Vertex, Viatris and Xenon Pharmaceuticals. He provided expert testimony for Janssen, Lundbeck, Neurocrine, and Otsuka. He served on a Data Safety Monitoring Board for Compass Pathways, IntraCellular Therapies, Relmada, Reviva, Rovi. He has received grant support from Boehringer-Ingelheim, Janssen and Takeda. He received royalties from UpToDate and is also a stock option or stock holder of Cardio Diagnostics, Kuleon Biosciences, LB Pharmaceuticals, MedLink Global, Mindpax, Quantic, Terran. J.M.R. has received honoraria from consulting for TEVA, Janssen, Bristol-Myers Squibb; grants from Bristol-Myers Squibb and Neurocrine; royalties from UpToDate. J.M.K. has received consultant or speaker fees from AbbVie, Alkermes, Allergan, Boehringer-Ingelheim, Bristol Myer-Squibb Cerevel, Click Therapeutics, Dainippon Sumitomo, H. Lundbeck, HealthRhythms, HLS Therapeutics, Intra-Cellular, Janssen, Johnson & Johnson, LB Pharmaceuticals, Mapi, Maplight, Merck, Minerva, Neurocrine, Newron, Novartis, NW PharmaTech, Otsuka, Roche, Saladax, Sunovion, Terran, and Teva; has grant support from Janssen, Lundbeck, Otsuka, Sunovion; receives royalties from UpToDate; and holds stock or stock options for Health Rhythms, LB Pharmaceuticals, Medincell, North Shore Therapeutics, NW Pharmatech, Reviva, Saladax, Terran, and Vanguard Research Group.
